Trial intelligence / Profile preview

10-valent pneumococcal conjugate vaccine booster or catch-up follow-up study in toddlers

2015-001449-93Phase 2

Sponsor
GSK
Start
Jun 2015
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Countries
1
01

Overview

Phase 2, single-blind trial of 10-valent pneumococcal conjugate vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Occurrence of grade 3 adverse events.

02

Drugs

10-valent pneumococcal conjugate vaccine
03

Conditions

pneumococcal disease

Beyond the preview

Go deeper on 2015-001449-93.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2015-001449-93.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call